Premium
Surgery Following Chemotherapy for Metastatic Testicular Teratoma
Author(s) -
WHILLIS D.,
COLEMAN R. E.,
LESSELLS A. M.,
HARGREAVE T. B.,
CORNBLEET M. A.,
HOWARD G. C.W.
Publication year - 1991
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1991.tb15326.x
Subject(s) - medicine , teratoma , chemotherapy , disease , surgery , minimal residual disease , presentation (obstetrics) , leukemia
Summary Twenty patients with metastatic testicular teratoma underwent surgery for residual disease after chemotherapy. Twelve patients in whom complete excision of all residual masses was possible are alive with no evidence of disease. Four patients have died of malignant teratoma, 2 have active malignant disease and 2 have inoperable residual cystic disease. Patients with malignant teratoma intermediate (MTI) primary testis tumours, and those with bulky abdominal disease at presentation, are more likely to have residual masses requiring excision. Completeness of excision appears to be the most important predictor of disease‐free survival.